Inovio Pharmaceuticals (INO) vs PMV Pharmaceuticals (PMVP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PMV Pharmaceuticals (PMVP) has outperformed Inovio Pharmaceuticals (INO) over the past year, gaining 4.9% versus a loss of 57.4%. Over five years, PMVP leads with a -93.8% price change compared with -98.7% for INO. Inovio Pharmaceuticals is the larger company by market cap ($112.7 million vs $112.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INO | PMVP |
|---|---|---|
| Share price | $1.09 | $1.49 |
| Market cap | $112.70M | $112.51M |
| 1-day change | -5.63% | -0.67% |
| YTD return | -37.36% | +19.20% |
| 1-year return | -57.42% | +4.93% |
| 5-year return | -98.71% | -93.78% |
| EPS (TTM) | $-0.90 | $-1.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.72 | $1.91 |
| 52-week low | $0.56 | $1.02 |
| Distance from 52-week high | -59.93% | -21.99% |
| Analyst consensus | none | none |
| Avg. price target upside | +190.83% | +181.88% |
| Average volume | 3.86M | 661.39K |
| Shares outstanding | 103.40M | 75.51M |
| Employees | 112 | 54 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PMVP has outperformed INO by 62.4 percentage points over the past year.
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees
INO vs PMVP FAQ
Which is bigger, Inovio Pharmaceuticals or PMV Pharmaceuticals?
Inovio Pharmaceuticals (INO) is larger, with a market capitalization of $112.70M compared with $112.51M for PMV Pharmaceuticals (PMVP).
Which stock has performed better over the past year, INO or PMVP?
PMVP returned +4.93% over the past 12 months, compared with -57.42% for INO (price return, excluding dividends). Past performance does not predict future results.
Are Inovio Pharmaceuticals and PMV Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.